A Case of Diffuse Infiltrative Hepatocellular Carcinoma with Marked Response to Sorafenib Treatment Evidenced by 18F-FDG PET/MRI

IF 0.9 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Molecular Imaging and Radionuclide Therapy Pub Date : 2024-04-16 DOI:10.4274/mirt.galenos.2024.36043

E. Özkan, Burak Demir, Diğdem Kuru Öz, Y. Ürün, N. O. Küçük

引用次数: 0

Abstract

A 73-year-old woman with known diagnosis of chronic hepatitis B infection referred for 18 F-fluorodeoxyglucose positron emission tomography/ computed tomography ( 18 F-FDG PET/CT) and magnetic resonance imaging (MRI) after detection of a liver mass with 9 cm diameter in contrast enhanced CT. However, 18 F-FDG PET/CT and MRI revealed diffuse infiltrating hepatocellular carcinoma lesions other than previously defined mass. After 9 months of Sorafenib treatment serum alpha feto protein levels dropped from 60,500 ng/mL to 801 ng/mL. Later 18 F-FDG PET/MRI was performed for evaluation of response to treatment and revealed marked response to treatment

查看原文本刊更多论文

一例通过 18F-FDG PET/MRI 证实对索拉非尼治疗有明显反应的弥漫浸润性肝细胞癌病例

一名 73 岁的妇女已知诊断为慢性乙型肝炎感染，在对比增强 CT 中发现一个直径 9 厘米的肝脏肿块，随后转诊到医院进行 18 F-FDG 正电子发射/计算机断层扫描（18 F-FDG PET/CT）和磁共振成像（MRI）检查。然而，18 F-FDG PET/CT 和核磁共振成像显示，除了之前确定的肿块外，还有弥漫浸润性肝细胞癌病灶。索拉非尼治疗9个月后，血清甲胎蛋白水平从60,500纳克/毫升降至801纳克/毫升。随后进行了 18 F-FDG PET/MRI，以评估治疗反应，结果显示治疗反应明显

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Imaging and Radionuclide Therapy RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： Molecular Imaging and Radionuclide Therapy (Mol Imaging Radionucl Ther, MIRT) is publishes original research articles, invited reviews, editorials, short communications, letters, consensus statements, guidelines and case reports with a literature review on the topic, in the field of molecular imaging, multimodality imaging, nuclear medicine, radionuclide therapy, radiopharmacy, medical physics, dosimetry and radiobiology.